CurrentMass General Brigham Health PlanPolicy N/A

Sephience (sepiapterin) prior authorization for phenylketonuria

Policy governs prior authorization and coverage criteria for Sephience (sepiapterin) for treatment of phenylketonuria (PKU) under the pharmacy benefit for Mass General Brigham Health Plan commercial/exchange members.

Policy Summary

PayerMass General Brigham Health Plan

PolicySephience (sepiapterin) prior authorization for phenylketonuria

Policy CodePolicy N/A

Change TypeNew policy

Effective DateMar 1, 2026

Next Review DateN/A

Key ActionSubmit prior authorization with documentation of PKU diagnosis, age (≥1 month), use with a Phe-restricted diet, baseline and follow-up Phe levels, and evidence of either classic PKU or trial/failure of sapropterin (Kuvan).

SourceLink

POLICY UPDATE CHANGES

Sephience (sepiapterin) coverage and prior authorization criteria for sepiapterin-responsive PKU were established with specific initial and reauthorization requirements.

1 monthminimum patient age for coverage

60 mg/kgmaximum dosage for stopping rule

15%required Phe decrease for continuation

3 monthsinitial authorization duration

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

reauthorization duration

Coverage Criteria for Sephience (sepiapterin)

Initial Authorization

Authorization may be granted when ALL of the following are met:

Primary authorization criteria

Diagnosis and age: Member has a diagnosis of phenylketonuria AND is 1 month of age or older.
Dietary use: Requested medication will be used in conjunction with a phenylalanine (Phe)-restricted diet.
Monitoring for new starts: For members starting therapy: Phe blood levels will be measured within two weeks of therapy and periodically for up to 3 months to determine response.
Qualification by PKU subtype or prior therapy: Member meets ONE of the following: (a) diagnosis of classic PKU (untreated serum Phe > 1200 micromol/L) OR (b) trial and failure, contraindication, or intolerance to sapropterin (Kuvan).
Monotherapy requirement: Requested medication will not be used in combination with another PKU drug, including a sapropterin-containing product and Palynziq (pegvaliase-pqpz).

Reauthorization / Continuation of Therapy

Requests for reauthorization will be approved when the following criteria are met:

Continuation criteria

Clinical response: Documentation member has had at least a 15% decrease in phenylalanine blood levels compared to baseline.>=15% decrease
Ongoing diet: Requested medication continues to be used in conjunction with a phenylalanine (Phe)-restricted diet.
Ongoing monitoring: Member continues to have blood Phe levels measured periodically during therapy.

Sephience (sepiapterin) will not be approved for use in combination with another pharmacologic therapy for phenylketonuria. Specifically, requests that propose concurrent use with sapropterin-containing products (e.g., Kuvan) or with pegvaliase (Palynziq) do not meet coverage criteria and will not be approved.

Initial Therapy Requirements

Initial Therapy

Initial approval criteria and monitoring

Initial therapy node: Indicated for patients ≥1 month with PKU, used with Phe-restricted diet; monitor Phe within 2 weeks and periodically up to 3 months; discontinue if Phe does not decrease after 2 weeks at maximum dose of 60 mg/kg. Member must meet classic PKU criteria or have trial/failure/intolerance/contraindication to sapropterin (Kuvan) if not classic PKU.

Continuation and Reauthorization Requirements

Continuation of Therapy

Reauthorization requirements

Continuation criteria node: Member must have ≥15% decrease in blood Phe from baseline, continue Phe-restricted diet, and have periodic Phe monitoring.>=15% decrease

Monitoring and Dosage Thresholds

Phenylalanine (Phe) blood level response

Continuation response thresholdMember must have at least a 15% decrease in phenylalanine (Phe) blood levels from baseline for reauthorization.

Initial monitoring timeframeMeasure Phe blood levels within 2 weeks of therapy initiation.

Ongoing monitoring periodPhe should be measured periodically for up to 3 months to determine response.

Maximum dosage evaluation period

Maximum dose stop ruleDiscontinue sepiapterin if blood Phe does not decrease after 2 weeks of treatment at the maximum dosage of 60 mg/kg.

Evaluation intervalAssess Phe response after 2 weeks on maximum tolerated dose.

Provider Responsibilities and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required under the pharmacy benefit for Sephience (sepiapterin) as a specialty medication.

Specialty pharmacy fill required
Pharmacy benefit prior authorization

Step Therapy

Step Therapy / Prior Therapy Consideration

Trial and failure, contraindication, or intolerance to sapropterin (Kuvan) is required as an alternative qualifying condition unless the member meets criteria for classic PKU.

Must document trial and failure, contraindication, or intolerance to sapropterin (Kuvan) OR documentation of classic PKU (untreated serum Phe > 1200 micromol/L)

Step Therapy and Alternative Qualifying Conditions

Acceptable alternative qualifying condition
Trial and failure, contraindication, or intolerance to sapropterin (Kuvan)

Site of Care and Dispensing

Billing Rule

Fill at contracted specialty pharmacy

Sephience has been designated a specialty medication and must be filled at a contracted specialty pharmacy under the pharmacy benefit.

Definitions Used in This Policy

Classic PKU

DefinitionClassic PKU: untreated serum phenylalanine concentrations > 1200 micromol/L.

Relevance to eligibilityMeeting classic PKU definition is one qualifying condition for initial authorization of sepiapterin.

Age considerationApplies in the context of patients 1 month of age or older being evaluated for therapy.

Sephience (sepiapterin)

Drug class and indicationSephience (sepiapterin) is a phenylalanine hydroxylase (PAH) activator indicated for treatment of hyperphenylalanemia in patients 1 month of age and older with sepiapterin-responsive PKU.

Use with dietMust be used in conjunction with a phenylalanine (Phe)-restricted diet.

Background

Sephience (sepiapterin) is a phenylalanine hydroxylase activator indicated for treatment of phenylketonuria (PKU) and must be used in conjunction with a phenylalanine (Phe)-restricted diet. Initial therapy requires the member be at least 1 month of age, with baseline and follow-up blood Phe monitoring — including a measurement within two weeks of therapy start and periodic measurements for up to 3 months to determine response.

Policy Summary

PayerMass General Brigham Health Plan

PolicySephience (sepiapterin) prior authorization for phenylketonuria

Policy CodePolicy N/A

Change TypeNew policy

Effective DateMar 1, 2026

Next Review DateN/A

SourceLink

On This Page

Action if inadequate responseStop therapy rather than continue beyond the 2-week maximum-dose evaluation period.

Documentation Required

Required Clinical Documentation

Documentation required includes diagnosis of phenylketonuria (PKU), age verification (≥1 month), evidence that Sephience will be used with a Phe-restricted diet, baseline and follow-up phenylalanine (Phe) blood level monitoring (within two weeks of therapy initiation and periodically for up to 3 months for new starts), and for continuation therapy documentation of at least a 15% decrease in Phe levels from baseline.

Diagnosis of PKU
Member is ≥ 1 month of age
Plan to use Sephience with a Phe‑restricted diet
Baseline Phe level and follow-up Phe levels (within 2 weeks of initiation and periodic monitoring up to 3 months)
For continuation: documentation of ≥ 15% decrease in Phe blood levels from baseline

Denial Risk

Concurrent PKU Therapy Exclusion

Use of Sephience in combination with another PKU drug is not allowed and will not meet criteria.

Combination therapy with sapropterin-containing products or pegvaliase (Palynziq) is excluded

Note

New-to-Plan Continuity Limitation

Members new to the plan within the past 90 days who are currently receiving the requested medication may be eligible for continuity of therapy; however, continuity does not apply if the product was obtained as samples or through manufacturer's patient assistance programs.

Continuity applies only to members actively receiving the medication at enrollment
Excludes products obtained as samples or via manufacturer patient assistance programs
New-to-plan continuity timeframe: within 90 days of plan enrollment

Discontinuation guidanceShould be discontinued if blood Phe does not decrease after 2 weeks at the maximum dosage of 60 mg/kg.